Ensysce Biosciences Expands Pain Treatment Pipeline with Strategic Acquisition
San Diego, Thursday, 13 August 2026.
Ensysce Biosciences completed its acquisition of Cy Biopharma, securing up to $77 million in potential funding and adding an Orphan Drug-designated pain candidate to advance into Phase 2 trials.
Acquisition Structure and Funding
Ensysce Biosciences, Inc. (NASDAQ: ENSC) officially finalized the acquisition of Cy Biopharma, Inc. on August 6, 2026, integrating the CY200 program for Complex Regional Pain Syndrome into its pipeline [1]. The transaction was structured as a stock-for-stock merger, accompanied by a concurrent private placement of Series C non-voting convertible preferred stock [1]. This financing round was led by Ally Bridge Group, with participation from Perceptive Advisors, Dellora Investments, Ikarian Capital, and Adage Capital Partners, L.P. [1]. The deal secures an initial funding injection of approximately $38.6 million, calculated by combining $17.1 million in cash from Cy Biopharma’s pre-acquisition convertible note financing and $21.5 million in gross proceeds from the preferred stock sale 38.6 [1]. Additional potential funding of up to $77 million is available contingent upon specific clinical milestones, extending the company’s financial runway into 2028 [1][2].
Acquisition Structure and Funding
The acquisition adds CY200, an FDA Orphan Drug-designated clinical-stage neuroplastogenic candidate, to Ensysce’s lead pipeline for CRPS Type 1 [1]. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, stated that the neuroplastogenic approach to complex pain represented the most compelling strategic opportunity explored by the company [1]. The company intends to utilize the proceeds from the private placement to advance CY200 through a randomized Phase 2 trial aimed at symptom alleviation for CRPS Type 1 [1]. This strategic move targets a pain market valued at over $1 billion, for which there is currently no approved therapy [1]. Tungsten Advisors served as the financial advisor to Ensysce Biosciences for this transaction [2].
Financial Performance and Cash Runway
In its second-quarter 2026 financial results reported on August 13, 2026, Ensysce disclosed a net loss of $2,570,709 for the quarter ending June 30, 2026 [1]. This compares to a net loss of $1,733,351 in the second quarter of 2025, representing an increase in losses 837358 over the prior year period [1]. As of June 30, 2026, the company held $0.7 million in cash and cash equivalents, a decrease from $4.3 million on December 31, 2025 [1]. Despite the losses, Ensysce holds a $15.1 million grant from the National Institute on Drug Abuse (NIDA) for its PF614-MPAR program, with $5.3 million of this funding remaining available through May 2027 [1].
Financial Performance and Cash Runway
Looking ahead, Ensysce Biosciences has scheduled a corporate update conference call for Tuesday, August 18, 2026, at 11:00 a.m. ET [1]. The call will feature CEO Dr. Lynn Kirkpatrick, President James Morrison, and Cy Biopharma CMO Professor Richard Langford [1]. Conference call access is available via U.S. dial-in at 1-877-407-9716 or international dial-in at 1-201-493-6779 [1]. A replay will be available from August 18, 2026, through Friday, September 18, 2026, using replay access ID 13762262 [1]. The company cautioned that as a clinical-stage biotech firm, continued research and development efforts are expected to result in losses for the foreseeable future [1].